Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.
Douglas K. Marks, MD
Advertisement
Articles by Douglas K. Marks, MD
Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.
Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Marks on the Role of TKIs in HER2-Positive Breast CancerSeptember 4th 2019
Dr. Marks on PHENIX Trial Data in HER2+ Breast CancerSeptember 9th 2019
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5